written by reader Anti-viral nano-constructs

By xiexgp@gmail.com, December 8, 2013

Anyone know more about this? sounds promising?

A pathbreaking flu drug is a huge step closer to human trials.

We’ve been on the case for over a year: Back then, there were already data demonstrating the treatment’s vast superiority to Tamiflu, the only flu drug on the market.

“The drug bases its technology on nano-sized polymer ‘decoys’ to induce viruses to harmlessly discharge their genetic material outside of a cell,” Ray and Stephen explain. “Its nano constructs aren’t designed to interact with human biology. Rather, they are designed to interact with viruses directly. This means the likelihood of off-target effects should be lower than with a traditional drug.”

Now come results from toxicology studies: “The compound produces no overt safety and toxicology effects, even at maximum dose levels. This includes an analysis of major organs such as the liver, kidneys and lungs.”

That’s critical as the company behind the compound prepares to submit its Investigational New Drug (IND) application to the FDA; evidence of safety must first be presented before human trials can start.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

1 Comment
Inline Feedbacks
View all comments
6 years ago

Why wouldn’t the introduction of protein structures cause an immune response the same way we vaccinate people today? Is the Nano technology too small for antibodies detection? Is there a possibility of the human defense system getting confused by these structures and attacking itself? This might be when the structures are by themselves or when they are associated or attached to the attacking viri.

Add a Topic

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info